{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T11:08:19Z","timestamp":1780312099230,"version":"3.54.0"},"reference-count":96,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2025,11,24]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>\n                    Pulmonary hypertension (PH) is a progressive and multifactorial disease marked by elevated pulmonary arterial pressure and right ventricular (RV) dysfunction. Among its subtypes, pulmonary arterial hypertension (PAH) is characterised by profound vascular remodelling, inflammation and fibrosis. Despite therapeutic advances targeting the endothelin, nitric oxide, prostacyclin, and, more recently, the activin signalling pathway\n                    <jats:italic>via<\/jats:italic>\n                    sotatercept, outcomes in PAH remain suboptimal, particularly in patients with cardiovascular comorbidities. This has prompted growing interest in novel metabolic-based interventions, such as glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs).\n                  <\/jats:p>\n                  <jats:p>GLP-1RAs, initially developed for type 2 diabetes and obesity, exhibit pleiotropic properties including vasodilation, anti-inflammatory, antifibrotic and endothelial-protective effects. In experimental models of PAH GLP-1RAs administration attenuates the severity of PH. Additional studies highlight their ability to protect against lung fibrosis and preserve endothelial function.<\/jats:p>\n                  <jats:p>Indirect enhancement of GLP-1 signalling through dipeptidyl peptidase-4 (DPP-4) inhibition similarly improves pulmonary haemodynamics and mitigates fibrosis and inflammation, underscoring the relevance of this pathway. Although no clinical trials have specifically evaluated GLP-1RAs in PH, observational studies in patients with heart failure with preserved ejection fraction suggest potential cardiopulmonary benefits.<\/jats:p>\n                  <jats:p>GLP-1RAs emerge as promising candidates bridging metabolic, vascular and cardiac domains in PH, warranting rigorous clinical validation. These findings support further translational research and randomised clinical trials to evaluate GLP-1RAs as a disease-modifying therapy in PAH.<\/jats:p>","DOI":"10.1183\/23120541.01479-2025","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T18:50:27Z","timestamp":1765479027000},"page":"01479-2025","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension"],"prefix":"10.1183","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6895-194X","authenticated-orcid":false,"given":"Benoit","family":"Aguado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3543-6675","authenticated-orcid":false,"given":"Thomas","family":"Lacoste-Palasset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6419-4332","authenticated-orcid":false,"given":"Gr\u00e9goire","family":"Ruffenach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9221-9688","authenticated-orcid":false,"given":"Fabrice","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-8975","authenticated-orcid":false,"given":"Laurent","family":"Savale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-2892","authenticated-orcid":false,"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-6922","authenticated-orcid":false,"given":"David","family":"Montani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9515-6571","authenticated-orcid":false,"given":"Fabrice","family":"Antigny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"2026060103401151000_12.3.01479-2025.1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01324-2024"},{"key":"2026060103401151000_12.3.01479-2025.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01095-2024"},{"key":"2026060103401151000_12.3.01479-2025.3","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0093-2017"},{"key":"2026060103401151000_12.3.01479-2025.4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01325-2024"},{"key":"2026060103401151000_12.3.01479-2025.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024277"},{"key":"2026060103401151000_12.3.01479-2025.6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2213558"},{"key":"2026060103401151000_12.3.01479-2025.7","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00668-2023"},{"key":"2026060103401151000_12.3.01479-2025.8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.chest.2023.08.023","article-title":"Managing pulmonary arterial hypertension with cardiopulmonary comorbidities","volume":"165","author":"Provencher","year":"2024","journal-title":"Chest"},{"key":"2026060103401151000_12.3.01479-2025.9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01887-2018"},{"key":"2026060103401151000_12.3.01479-2025.10","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0094-2017"},{"key":"2026060103401151000_12.3.01479-2025.11","doi-asserted-by":"publisher","DOI":"10.4103\/2045-8932.109960"},{"key":"2026060103401151000_12.3.01479-2025.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2020.09.011"},{"key":"2026060103401151000_12.3.01479-2025.13","doi-asserted-by":"crossref","first-page":"957524","DOI":"10.3389\/fcvm.2022.957524","article-title":"Metabolic reprogramming: a novel metabolic model for pulmonary hypertension","volume":"9","author":"Liu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026060103401151000_12.3.01479-2025.14","doi-asserted-by":"crossref","first-page":"935423","DOI":"10.3389\/fcvm.2022.935423","article-title":"Comparative analysis of right ventricular metabolic reprogramming in pre-clinical rat models of severe pulmonary hypertension-induced right ventricular failure","volume":"9","author":"Banerjee","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026060103401151000_12.3.01479-2025.15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/nrcardio.2017.188","article-title":"Promising mitochondria-targeting drug for PAH","volume":"15","author":"Fern\u00e1ndez-Ruiz","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2026060103401151000_12.3.01479-2025.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"2026060103401151000_12.3.01479-2025.17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.114.301958"},{"key":"2026060103401151000_12.3.01479-2025.18","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2011.149"},{"key":"2026060103401151000_12.3.01479-2025.19","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00574.2023"},{"key":"2026060103401151000_12.3.01479-2025.20","doi-asserted-by":"crossref","first-page":"113236","DOI":"10.1016\/j.biopha.2022.113236","article-title":"Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases","volume":"152","author":"Yang","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"2026060103401151000_12.3.01479-2025.21","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1186\/s12967-024-05753-z","article-title":"GLP-1R activation attenuates the progression of pulmonary fibrosis via disrupting NLRP3 inflammasome\/PFKFB3-driven glycolysis interaction and histone lactylation","volume":"22","author":"Liu","year":"2024","journal-title":"J Transl Med"},{"key":"2026060103401151000_12.3.01479-2025.22","doi-asserted-by":"publisher","DOI":"10.1161\/atv.0000615456.97862.30"},{"key":"2026060103401151000_12.3.01479-2025.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01344-2024"},{"key":"2026060103401151000_12.3.01479-2025.24","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12028"},{"key":"2026060103401151000_12.3.01479-2025.25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"2026060103401151000_12.3.01479-2025.26","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/cvr\/cvae120","article-title":"Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node","volume":"120","author":"Lubberding","year":"2024","journal-title":"Cardiovasc Res"},{"key":"2026060103401151000_12.3.01479-2025.27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.028136"},{"key":"2026060103401151000_12.3.01479-2025.28","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3389\/fphar.2019.00537","article-title":"The GLP-1 analog liraglutide protects against angiotensin II and pressure overload-induced cardiac hypertrophy via PI3K\/Akt1 and AMPKa signaling","volume":"10","author":"Li","year":"2019","journal-title":"Front Pharmacol"},{"key":"2026060103401151000_12.3.01479-2025.29","doi-asserted-by":"crossref","first-page":"8284","DOI":"10.1038\/s41598-020-64924-2","article-title":"Intermittent use of a short-course glucagon-like peptide-1 receptor agonist therapy limits adverse cardiac remodeling via parkin-dependent mitochondrial turnover","volume":"10","author":"Germano","year":"2020","journal-title":"Sci Rep"},{"key":"2026060103401151000_12.3.01479-2025.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62465-6"},{"key":"2026060103401151000_12.3.01479-2025.31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1148209"},{"key":"2026060103401151000_12.3.01479-2025.32","doi-asserted-by":"crossref","first-page":"678055","DOI":"10.3389\/fendo.2021.678055","article-title":"The interplay of glucagon-like peptide-1 receptor trafficking and signalling in pancreatic beta cells","volume":"12","author":"Marzook","year":"2021","journal-title":"Front Endocrinol"},{"key":"2026060103401151000_12.3.01479-2025.33","doi-asserted-by":"publisher","DOI":"10.1210\/en.2018-00004"},{"key":"2026060103401151000_12.3.01479-2025.34","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3128"},{"key":"2026060103401151000_12.3.01479-2025.35","doi-asserted-by":"crossref","first-page":"18091","DOI":"10.1038\/s41598-020-74912-1","article-title":"GLP-1 receptor agonist ameliorates experimental lung fibrosis","volume":"10","author":"Fandi\u00f1o","year":"2020","journal-title":"Sci Rep"},{"key":"2026060103401151000_12.3.01479-2025.36","doi-asserted-by":"publisher","DOI":"10.2337\/db13-1440"},{"key":"2026060103401151000_12.3.01479-2025.37","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.118.006740"},{"key":"2026060103401151000_12.3.01479-2025.38","doi-asserted-by":"crossref","first-page":"101641","DOI":"10.1016\/j.molmet.2022.101641","article-title":"Glucagon-like peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction","volume":"66","author":"McLean","year":"2022","journal-title":"Mol Metab"},{"key":"2026060103401151000_12.3.01479-2025.39","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"key":"2026060103401151000_12.3.01479-2025.40","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1666"},{"key":"2026060103401151000_12.3.01479-2025.41","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1934"},{"key":"2026060103401151000_12.3.01479-2025.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001"},{"key":"2026060103401151000_12.3.01479-2025.43","doi-asserted-by":"publisher","DOI":"10.1177\/20406223221108064"},{"key":"2026060103401151000_12.3.01479-2025.44","doi-asserted-by":"crossref","first-page":"e133429","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"2026060103401151000_12.3.01479-2025.45","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-022-09735-8"},{"key":"2026060103401151000_12.3.01479-2025.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2010.12.016"},{"key":"2026060103401151000_12.3.01479-2025.47","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15134"},{"key":"2026060103401151000_12.3.01479-2025.48","doi-asserted-by":"crossref","unstructured":"Latif W , Lambrinos KJ , Patel P , et al. Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs). StatPearls Treasure Island, StatPearls Publishing, 2025 www.ncbi.nlm.nih.gov\/books\/NBK572151\/","DOI":"10.31031\/NPMS.2025.01.000518"},{"key":"2026060103401151000_12.3.01479-2025.49","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.2147\/DDDT.S506957","article-title":"A comprehensive review on the pharmacokinetics and drug\u2212drug interactions of approved GLP-1 receptor agonists and a dual GLP-1\/GIP receptor agonist","volume":"19","author":"Min","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"2026060103401151000_12.3.01479-2025.50","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011395"},{"key":"2026060103401151000_12.3.01479-2025.51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01663.x"},{"key":"2026060103401151000_12.3.01479-2025.52","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2025.0106"},{"key":"2026060103401151000_12.3.01479-2025.53","doi-asserted-by":"crossref","first-page":"2402250","DOI":"10.1183\/13993003.02250-2024","article-title":"Pharmacological inhibition of Epac1 protects against pulmonary fibrosis by blocking FoxO3a neddylation","volume":"64","author":"Jankowski","year":"2025","journal-title":"Eur Respir J"},{"key":"2026060103401151000_12.3.01479-2025.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahjo.2025.100555"},{"key":"2026060103401151000_12.3.01479-2025.55","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4093\/dmj.2022.0363","article-title":"Glucagon-like peptide receptor agonist inhibits angiotensin II-induced proliferation and migration in vascular smooth muscle cells and ameliorates phosphate-induced vascular smooth muscle cells calcification","volume":"48","author":"Lee","year":"2024","journal-title":"Diabetes Metab J"},{"key":"2026060103401151000_12.3.01479-2025.56","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01524-2018"},{"key":"2026060103401151000_12.3.01479-2025.57","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01700-2019"},{"key":"2026060103401151000_12.3.01479-2025.58","doi-asserted-by":"crossref","first-page":"1079989","DOI":"10.3389\/fphys.2022.1079989","article-title":"Mitochondrial dysfunction in pulmonary arterial hypertension","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Physiol"},{"key":"2026060103401151000_12.3.01479-2025.59","doi-asserted-by":"crossref","first-page":"1283233","DOI":"10.3389\/fendo.2023.1283233","article-title":"Pulmonary hypertension and insulin resistance: a mechanistic overview","volume":"14","author":"Zanotto","year":"2024","journal-title":"Front Endocrinol"},{"key":"2026060103401151000_12.3.01479-2025.60","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03957-2020"},{"key":"2026060103401151000_12.3.01479-2025.61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1821401116"},{"key":"2026060103401151000_12.3.01479-2025.62","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.019351"},{"key":"2026060103401151000_12.3.01479-2025.63","doi-asserted-by":"crossref","first-page":"923606","DOI":"10.3389\/fendo.2022.923606","article-title":"GLP-1 RAs and SGLT-2 inhibitors for insulin resistance in nonalcoholic fatty liver disease: systematic review and network meta-analysis","volume":"13","author":"Yan","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026060103401151000_12.3.01479-2025.64","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0161-2021"},{"key":"2026060103401151000_12.3.01479-2025.65","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00314-2020"},{"key":"2026060103401151000_12.3.01479-2025.66","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/immuno5010011","article-title":"Anti-inflammatory and anti-oxidative effects of GLP1-RAs and SGLT2i: the guiding star towards cardiovascular protection in type 2 diabetes","volume":"5","author":"Marcon","year":"2025","journal-title":"Immuno"},{"key":"2026060103401151000_12.3.01479-2025.67","doi-asserted-by":"crossref","first-page":"e22482","DOI":"10.1016\/j.heliyon.2023.e22482","article-title":"Adipokines in pulmonary hypertension: angels or demons?","volume":"9","author":"Jia","year":"2023","journal-title":"Heliyon"},{"key":"2026060103401151000_12.3.01479-2025.68","doi-asserted-by":"publisher","DOI":"10.1177\/2045894020952023"},{"key":"2026060103401151000_12.3.01479-2025.69","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00193014"},{"key":"2026060103401151000_12.3.01479-2025.70","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2010-0316OC"},{"key":"2026060103401151000_12.3.01479-2025.71","doi-asserted-by":"crossref","first-page":"e0169469","DOI":"10.1371\/journal.pone.0169469","article-title":"Exendin-4 upregulates adiponectin level in adipocytes via Sirt1\/Foxo-1 signaling pathway","volume":"12","author":"Wang","year":"2017","journal-title":"PLoS One"},{"key":"2026060103401151000_12.3.01479-2025.72","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14855"},{"key":"2026060103401151000_12.3.01479-2025.73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"2026060103401151000_12.3.01479-2025.74","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02526-x"},{"key":"2026060103401151000_12.3.01479-2025.75","doi-asserted-by":"crossref","first-page":"2002258","DOI":"10.1183\/13993003.02258-2020","article-title":"Sleep-related breathing disorders and pulmonary hypertension","volume":"57","author":"Adir","year":"2021","journal-title":"Eur Respir J"},{"key":"2026060103401151000_12.3.01479-2025.76","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0\u2009mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes (Lond)"},{"key":"2026060103401151000_12.3.01479-2025.77","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48970-2"},{"key":"2026060103401151000_12.3.01479-2025.78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404881"},{"key":"2026060103401151000_12.3.01479-2025.79","doi-asserted-by":"crossref","first-page":"e32229","DOI":"10.1016\/j.heliyon.2024.e32229","article-title":"Liraglutide ameliorates TAC-induced cardiac hypertrophy and heart failure by upregulating expression level of ANP expression","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"2026060103401151000_12.3.01479-2025.80","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3389\/fphys.2018.00472","article-title":"Pathophysiological mapping of experimental heart failure: left and right ventricular remodeling in transverse aortic constriction is temporally, kinetically and structurally distinct","volume":"9","author":"Platt","year":"2018","journal-title":"Front Physiol"},{"key":"2026060103401151000_12.3.01479-2025.81","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.3390\/biomedicines12092112","article-title":"The emerging role of glucagon-like peptide-1 receptor agonists in the management of obesity-related heart failure with preserved ejection fraction: benefits beyond what scales can measure?","volume":"12","author":"Karakasis","year":"2024","journal-title":"Biomedicines"},{"key":"2026060103401151000_12.3.01479-2025.82","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/ehjcvp\/pvad072","article-title":"GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity","volume":"9","author":"Kato","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026060103401151000_12.3.01479-2025.83","doi-asserted-by":"crossref","first-page":"983961","DOI":"10.3389\/fphys.2022.983961","article-title":"The potential of glucagon-like peptide-1 receptor agonists in heart failure","volume":"13","author":"Kreiner","year":"2022","journal-title":"Front Physiol"},{"key":"2026060103401151000_12.3.01479-2025.84","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.jchf.2024.07.006","article-title":"GLP-1 receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 inhibitors","volume":"12","author":"Patel","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026060103401151000_12.3.01479-2025.85","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.cardfail.2024.10.448","article-title":"GLP-1 receptor agonist in nonobese patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction","volume":"31","author":"Khadke","year":"2025","journal-title":"J Card Fail"},{"key":"2026060103401151000_12.3.01479-2025.86","doi-asserted-by":"publisher","DOI":"10.4103\/2045-8932.109954"},{"key":"2026060103401151000_12.3.01479-2025.87","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.008750"},{"key":"2026060103401151000_12.3.01479-2025.88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963"},{"key":"2026060103401151000_12.3.01479-2025.89","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.3390\/ijms20143435","article-title":"Glucagon-like peptide-1 receptor agonist attenuates autophagy to ameliorate pulmonary arterial hypertension through Drp1\/NOX and Atg-5\/Atg-7\/Beclin-1\/LC3\u03b2 pathways","volume":"20","author":"Wu","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026060103401151000_12.3.01479-2025.90","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cardfail.2024.09.009","article-title":"Highlights for the heart failure cardiologist from the seventh world symposium on pulmonary hypertension: are we out of the woods yet?","volume":"31","author":"Cascino","year":"2025","journal-title":"J Card Fail"},{"key":"2026060103401151000_12.3.01479-2025.91","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac237"},{"key":"2026060103401151000_12.3.01479-2025.92","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-019-0496-y"},{"key":"2026060103401151000_12.3.01479-2025.93","doi-asserted-by":"crossref","first-page":"31788","DOI":"10.1038\/srep31788","article-title":"Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS\/sGC\/PKG pathways","volume":"6","author":"Lee","year":"2016","journal-title":"Sci Rep"},{"key":"2026060103401151000_12.3.01479-2025.94","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3390\/ijms25020748","article-title":"Functional roles of CD26\/DPP4 in bleomycin-induced pulmonary hypertension associated with interstitial lung disease","volume":"25","author":"Okaya","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026060103401151000_12.3.01479-2025.95","doi-asserted-by":"publisher","DOI":"10.1038\/s41374-018-0080-1"},{"key":"2026060103401151000_12.3.01479-2025.96","doi-asserted-by":"crossref","first-page":"E568","DOI":"10.1152\/ajpendo.00292.2020","article-title":"Glucagon-like peptide-1 receptor mediates the beneficial effect of liraglutide in an acute lung injury mouse model involving the thioredoxin-interacting protein","volume":"319","author":"Zhou","year":"2020","journal-title":"Am J Physiol Endocrinol Metab"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01479-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T10:40:22Z","timestamp":1780310422000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01479-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":96,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6,1]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1183\/23120541.01479-2025"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01479-2025","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]}}}